274 related articles for article (PubMed ID: 17245355)
1. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
[TBL] [Abstract][Full Text] [Related]
3. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E
J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
Baertsch MA; Leber MF; Bossow S; Singh M; Engeland CE; Albert J; Grossardt C; Jäger D; von Kalle C; Ungerechts G
Cancer Gene Ther; 2014 Sep; 21(9):373-80. PubMed ID: 25145311
[TBL] [Abstract][Full Text] [Related]
5. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
6. Generation of recombinant measles virus containing the wild-type P gene to improve its oncolytic efficiency.
Alizadeh R; Ghanei M; Arashkia A; Dorostkar R; Azadmanesh K
Microb Pathog; 2019 Oct; 135():103631. PubMed ID: 31381964
[No Abstract] [Full Text] [Related]
7. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
[TBL] [Abstract][Full Text] [Related]
8. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
9. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
11. Measles virus for cancer therapy.
Russell SJ; Peng KW
Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
[TBL] [Abstract][Full Text] [Related]
12. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
13. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
[TBL] [Abstract][Full Text] [Related]
14. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
15. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
[TBL] [Abstract][Full Text] [Related]
16. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
17. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.
Xia M; Gonzalez P; Li C; Meng G; Jiang A; Wang H; Gao Q; Debatin KM; Beltinger C; Wei J
J Virol; 2014 May; 88(9):5152-64. PubMed ID: 24574393
[TBL] [Abstract][Full Text] [Related]
18. The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.
Dey A; Zhang Y; Castleton AZ; Bailey K; Beaton B; Patel B; Fielding AK
Mol Ther; 2016 Feb; 24(1):184-92. PubMed ID: 26278331
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
20. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
